Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Among authors: baldoni a. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy.
Nicoletto MO, Casarin A, Baldoni A, Rulli E, Tasca G, Baretta Z, Artioli G, Lombardi G, Cappetta A, Floriani I, Randon G, Valpione S, Litta P, Conte P, Mocellin S, Aliberti C. Nicoletto MO, et al. Among authors: baldoni a. Anticancer Res. 2016 Dec;36(12):6541-6546. doi: 10.21873/anticanres.11256. Anticancer Res. 2016. PMID: 27919980
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Daniele G, Lorusso D, Scambia G, Cecere SC, Nicoletto MO, Breda E, Colombo N, Artioli G, Cannella L, Lo Re G, Raspagliesi F, Maltese G, Salutari V, Ferrandina G, Greggi S, Baldoni A, Bergamini A, Piccirillo MC, Tognon G, Floriani I, Signoriello S, Perrone F, Pignata S. Daniele G, et al. Among authors: baldoni a. Gynecol Oncol. 2017 Feb;144(2):256-259. doi: 10.1016/j.ygyno.2016.12.011. Epub 2016 Dec 16. Gynecol Oncol. 2017. PMID: 27993479 Clinical Trial.
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M. Colombo N, et al. Among authors: baldoni a. Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20. Br J Cancer. 2019. PMID: 31537908 Free PMC article. Clinical Trial.
Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer.
Nicoletto MO, Baldoni A, Cavallin F, Grego A, Falci C, Nardin M, Mammano E, Lai E, Torri V. Nicoletto MO, et al. Among authors: baldoni a. Ther Adv Med Oncol. 2023 Jun 21;15:17588359231173181. doi: 10.1177/17588359231173181. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37360767 Free PMC article.
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Turinetto M, Ricotti A, Marchetti C, Pisano C, Zamagni C, Cassani C, Malaguti P, Baldoni A, Scollo P, Scandurra G, Parisi A, Artioli G, Palaia I, Vertechy L, Bergamini A, Picardo E, Tuninetti V, Scotto G, Scambia G, Pignata S, Valabrega G. Turinetto M, et al. Among authors: baldoni a. Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041. Cancers (Basel). 2023. PMID: 38201470 Free PMC article.
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.
Dieci MV, Azzarello G, Zagonel V, Bassan F, Gori S, Aprile G, Chiarion-Sileni V, Lonardi S, Oliani C, Zaninelli M, Chiari R, Favaretto A, Pavan A, Di Liso E, Mioranza E, Baldoni A, Bergamo F, Maruzzo M, Ziampiri S, Inno A, Graziani F, Sinigaglia G, Celestino M, Conte P, Guarneri V; Veneto Oncology Network. Dieci MV, et al. Among authors: baldoni a. Eur J Cancer. 2022 May;167:81-91. doi: 10.1016/j.ejca.2022.03.005. Epub 2022 Mar 18. Eur J Cancer. 2022. PMID: 35398759 Free PMC article.
105 results